Colleran David 4

What Happened

• David Colleran, EVP, General Counsel and Corporate Secretary of Anika Therapeutics (ANIK), had multiple equity awards vest over March 14–15, 2026. On March 14 he received 9,388 shares from an RSU grant plus 4,694 shares from a performance-PSU installment (total 14,082 shares). On March 15 he received 6,449 shares (a scheduled RSU installment).
• The company withheld shares to satisfy tax withholding: per the filing, 4,694 shares were retained on March 14 and 1,893 shares were retained on March 15. The withholding transactions are shown as resulting in proceeds of $59,186 (Mar 14) and $26,881 (Mar 15), an aggregate of about $86,067. These were withholding transactions tied to vesting, not open‑market sales.

Key Details

• Transaction dates: March 14, 2026 and March 15, 2026.
• Vesting/convert events (code M/A): 9,388 shares (RSU vesting) and 4,694 shares (PSU vesting) on 3/14; 6,449 shares (RSU installment) on 3/15.
• Tax withholding (code F): issuer retained 4,694 shares (3/14) and 1,893 shares (3/15); filing shows withheld-share cash values of $59,186 and $26,881 respectively.
• Origin of awards (footnotes): 14,082 PSUs granted 3/14/2025 (1/3 vested 3/14/2026); 28,165 RSUs granted 3/14/2025 (1/3 vested 3/14/2026); 19,345 RSUs granted 3/15/2024 (second installment vested 3/15/2026).
• Shares owned after transaction: not specified in the provided excerpt.
• Filing timeliness: no late‑filing indication in the provided information.

Context

• These transactions are routine vesting and withholding events (awards converting to shares with company withholding some shares for taxes). They are not open‑market purchases or discretionary sales by the insider, so they generally reflect compensation settlement rather than a trading decision.
• For derivative entries (code M): the filing shows conversion/exercise-type entries reflecting RSUs/PSUs settling into common shares. For withholding (code F): shares were surrendered/retained to cover taxes rather than sold on the open market.